Social media

Only one day until #OCT Southeast begins. ICON will be on site 10–11 March, ready to connect with biotechs looking to strengthen clinical delivery. Visit Booth #37 to meet our team and discuss how our expertise supports ...

Meet the ICON team at Medidata NEXT New York. Our specialists will be available throughout the event to discuss how ICON is supporting sponsors to improve study build quality, streamline delivery and adopt technology wit...

Meet the ICON team at Medidata NEXT New York. Our specialists will be available throughout the event to discuss how ICON is supporting sponsors to improve study build quality, streamline delivery and adopt technology wit...

A multi phase ICON supported study details the leading symptoms in advanced/metastatic HCC including fatigue, weight loss, weakness, appetite loss, and sleep disturbance. Findings show wide ranging effects on daily fun...

A multi phase ICON supported study details the leading symptoms in advanced/metastatic HCC including fatigue, weight loss, weakness, appetite loss, and sleep disturbance. Findings show wide ranging effects on daily fun...

ICON is proud to be recognised among the top global companies in the world for female employees. As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful refle...

ICON is proud to be recognised among the top global companies in the world for female employees. This recognition is based on a comprehensive survey of approximately 120,000 women across more than 36 countries, highlight...

Join Steve Hunt at Medidata NEXT New York for a roundtable discussion on real world lessons from early adopters of Medidata Designer. Steve will share what effective adoption looks like in practice, where ICON teams are ...

Join Steve Hunt at Medidata NEXT New York for a roundtable discussion on real world lessons from early adopters of Medidata Designer. Steve will share what effective adoption looks like in practice, where ICON teams are ...

The oncology R&D landscape is rapidly evolving, driven by multi‑modality therapeutics, precision‑designed studies, and the growing measurable impact of AI on discovery and development. These shifts are reshaping how spon...

The oncology R&D landscape is rapidly evolving, driven by multi‑modality therapeutics, precision‑designed studies, and the growing measurable impact of AI on discovery and development. These shifts are reshaping how spon...

Last week, our teams across ICON came together to recognise Rare Disease Day and raise awareness for the millions of people and families living with rare conditions. Colleagues took part in activities including creating...